LAVA Therapeutics NV

LAVA Therapeutics NV operates as an immuno-oncology company. It utilizing its proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies

LAVA Therapeutics Announces Two Appointments to its Board of Directors

UTRECHT, The Netherlands and PHILADELPHIA, June 02, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Healthcare Conference being held in New York, NY.

LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. CEST LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. CEST

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

UTRECHT, The Netherlands and PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Annual General Meeting of Shareholders will take place on Wednesday, June 15, 2022, at 7:30 a.m. CEST, at Beethovenstraat 400, 1082 PR, Amsterdam, the Netherlands.

LAVA Therapeutics Announces Annual Meeting of Shareholders

UTRECHT, The Netherlands and PHILADELPHIA, May 17, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced recent corporate highlights and financial results for the first quarter ended March 31, 2022.

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

LAVA Therapeutics (LVTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why LAVA Therapeutics (LVTX) Might Surprise This Earnings Season

UTRECHT, The Netherlands and PHILADELPHIA, May 12, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for LAVA-051, the Company's lead product candidate for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML).

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 being held in New York, NY.

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022.

LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2021.

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

UTRECHT, The Netherlands and PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present the latest company overview at the Oppenheimer 32 nd  Annual Healthcare Conference 2022. The conference is being conducted in a virtual format and the presentation will take place on Thursday, Mar. 17, 2022 from 8:40 – 9:10 a.m. ET.

LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022

LAVA Therapeutics NV (NASDAQ: LVTX) announced initial data from its first clinical study with LAVA-051.  The presentation will include data from the first three cohorts of the LAVA-051 Phase 1/2a trial, along with preclinical data on its two lead programs, LAVA-051 and LAVA-.

LAVA Therapeutics Shares Interim LAVA-051 Data From Early-Stage Cancer Trial

UTRECHT, The Netherlands and PHILADELPHIA, March 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced initial data from its first clinical study with LAVA-051. LAVA chief scientific officer Hans van der Vliet, M.D., Ph.D. will deliver the presentation “Bispecific γδ T cell engagers for the treatment of cancer” during the Bispecifics and T cell Engagers session in the Channel 1 virtual room today from 14.35 – 14.55 CET at the ESMO Targeted Anticancer Therapies Congress 2022. The presentation will include data from the first three cohorts of the LAVA-051 Phase 1/2a clinical trial along with preclinical data on its two lead programs, LAVA-051 and LAVA-1207, that illustrate characteristics of its Gammabody™ platform.

LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022

LAVA's Lead Solid Tumor Program and Second Gammabody™ T cell Engager Enters the Clinic LAVA's Lead Solid Tumor Program and Second Gammabody™ T cell Engager Enters the Clinic

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer

Zynga

APA Corporation

Centennial Resource Development

HighPeak Energy Inc

These top-ranked Nasdaq stocks returned more than 20% in January despite the index's downbeat performance.

Nasdaq ETFs to Log Worst Month Since 2008? 5 Stocks Up 20%+

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present the latest company overview at the SVB Leerink 11th Annual Global Healthcare Conference 2022. The conference is being conducted in a virtual format and the presentation will take place on Thursday, Feb. 17, 2022 at 8:40 a.m. ET.

Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022

The collective data indicate that LAVA's approach to recruit gamma delta T cells with its bispecific antibody platform results in potent anti-tumor activity while avoiding off-tumor toxicity and cytokine release syndrome (CRS), potentially translating in a superior therapeutic index compared to CD3-based T cell engagers

LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note the date in the first paragraph should be Wednesday, Jan. 12, 2022 at 1:30 p.m. EST instead of Wednesday, Jan. 12, 2021 at 1:30 p.m. EST. Completed corrected text follows.

CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, chief executive officer, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2021 at 1:30 p.m. EST.

LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that LAVA and The Antibody Society, a non-profit association, are co-organizing a virtual symposium Emerging cancer therapies leveraging gamma-delta effector T cells taking place on Mon., Nov. 29, 2021 from 11 a.m. to 2 p.m. EST / 17.00 to 20.00 CET.

LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced the expansion of its management team with the appointments of  Jessica Truscello as vice president of clinical operations, Sumeet Ambarkhane, M.D. as executive medical director and Wouter van Hunnik as vice president of human resources.

LAVA Therapeutics Expands Management Team with Three Key Appointments

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer at LAVA, will participate in a virtual fireside chat for the 12th Annual Jefferies London Healthcare Conference taking place from Nov. 16-19, 2021. Members of the LAVA leadership team will also participate in virtual one-to-one investor meetings during the conference.

LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference

Paul W.H.I. Parren, Ph.D., EVP, Head of R&D to share data regarding LAVA bispecific gamma delta T cell engagers derived from proprietary Gammabody™ platform Paul W.H.I. Parren, Ph.D., EVP, Head of R&D to share data regarding LAVA bispecific gamma delta T cell engagers derived from proprietary Gammabody™ platform

LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company's CD1d targeted Gammabody TM , LAVA-051, for the treatment of chronic lymphocytic leukemia (CLL). CLL is a form of leukemia characterized by progressive accumulation of abnormal lymphocytes in the peripheral blood, bone marrow and lymphoid tissues.

LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note that in the second paragraph Vγ9Vδ2 T cells were incorrectly written as V9V2 T cells. The corrected release follows:

CORRECTING and REPLACING: LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

News for LAVA Therapeutics NV Stock (LVTX)